BioLogic QuadTec UV/Vis detector for simultaneous monitoring of four wavelengths ranging from 190–740 nm (with deuterium lamp at 190–370 nm and optional halogen lamp at 370–740 nm) ...

If you have Crohn’s disease that is not responding well to other medications, a doctor may prescribe biologic drugs. Common side effects of biologics include headache, fever, and pain around the ...

Newark, April 25, 2024 (GLOBE NEWSWIRE) -- The Brainy Insights estimates that the USD 469.7 billion biologic therapeutics drugs market will reach USD 1485.0 billion by 2033. Biologic therapeutics ...

Minneapolis, Minnesota--(Newsfile Corp. - May 3, 2024) - Sonnet BioTherapeutics Holdings, Inc. (NASDAQ: SONN), a biopharmaceutical company developing innovative targeted biologic drugs, will be ...

An Orangeburg prosthetics and orthotics practice has moved into a larger space. BioLogic P&O LLC has expanded its business to ...

Biologic response modifiers, which are based on proteins made by living cells, are newer agents available for the treatment of various inflammatory joint diseases. Biologic therapies now approved ...

THE following remarks on current trends in biologic products, not being based on a careful survey of current literature or opinion, represent only an expression of the impressions gained through ...

A person may find that symptoms of psoriatic arthritis (PsA) return when they stop biologic treatment. Still, stopping may be necessary in some instances, such as before and during pregnancy ...

China Biologic Products, Inc. operates as a biopharmaceutical company, which engages in the manufacture and distribution of plasma-based pharmaceutical products and other biological substances.

SAN DIEGO – SYNC-T, an investigational therapy that combines a device-induced vaccination at the tumor site with intratumoral infusion of a multitarget biologic drug led to numerous clinical ...

Sidney Chiropractic has recently added regenerative therapy to its list of treatments. The regenerative therapy consists of ...

Completed additional enrollment in Phase 1B dose-expansion cohorts for TP53 mutant (TP53m) Acute Myeloid Leukemia (AML) patients in the first ...